Physicians have remaining safety concerns about the multiple sclerosis drug Tysabri, which returned to the market in July, and the risk of a rare, fatal brain disease, according to findings from a Reuters survey. Partly because of that fear, the Biogen Idec and Elan Corp. drug is falling short of analyst projections of more than $100 million in sales.

Related Summaries